Teleflex Incorporated (NYSE:TFX) Stock Has Consensus Price Target of $155.20

Teleflex Incorporated (NYSE:TFX) has earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $155.20.

A number of research analysts recently weighed in on TFX shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a research report on Monday, September 21st. Piper Sandler reissued an “overweight” rating and set a $169.00 price objective (up from $160.00) on shares of Teleflex in a research report on Friday, August 7th. Mizuho raised their price objective on shares of Teleflex from $140.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Zacks Research raised shares of Teleflex from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 24th. Finally, Wall Street Zen upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a research note on Sunday, August 9th.

Teleflex Trading Down 0.1%

TFX opened at $124.36 on Tuesday. The company has a quick ratio of 2.12, a current ratio of 2.60 and a debt-to-equity ratio of 0.94. Teleflex has a 52 week low of $100.18 and a 52 week high of $145.00. The stock has a market cap of $5.27 billion, a PE ratio of -5.34, a PEG ratio of 0.83 and a beta of 0.83. The business has a 50 day moving average of $132.58 and a 200-day moving average of $129.71.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.48. The company had revenue of $570.33 million for the quarter, compared to analysts’ expectations of $559.59 million. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The firm’s revenue for the quarter was up 28.9% on a year-over-year basis. During the same period in the prior year, the firm earned $3.73 earnings per share. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Equities research analysts predict that Teleflex will post 7.22 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Friday, August 14th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $1.36 annualized dividend and a yield of 1.1%. Teleflex’s payout ratio is currently -5.84%.

Hedge Funds Weigh In On Teleflex

Hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC increased its position in shares of Teleflex by 9.8% during the 3rd quarter. GAMMA Investing LLC now owns 921 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 82 shares during the last quarter. Hsbc Holdings PLC raised its stake in shares of Teleflex by 4.7% in the first quarter. Hsbc Holdings PLC now owns 1,861 shares of the medical technology company’s stock valued at $222,000 after acquiring an additional 84 shares during the period. Leonteq Securities AG lifted its holdings in shares of Teleflex by 13.6% in the 1st quarter. Leonteq Securities AG now owns 1,164 shares of the medical technology company’s stock worth $139,000 after acquiring an additional 139 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Teleflex by 3.4% in the 4th quarter. CIBC Asset Management Inc now owns 4,380 shares of the medical technology company’s stock worth $535,000 after acquiring an additional 145 shares during the last quarter. Finally, Sage Rhino Capital LLC boosted its stake in shares of Teleflex by 9.5% during the 1st quarter. Sage Rhino Capital LLC now owns 1,837 shares of the medical technology company’s stock worth $220,000 after purchasing an additional 159 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, physicians and other healthcare providers. Its products are designed to support minimally invasive procedures, critical care and a range of clinical applications.

The company’s portfolio includes devices for vascular access and intervention, anesthesia, respiratory care, emergency medicine, surgery, urology and pain management. Teleflex markets products under brands including Arrow, which is known for vascular access and catheter-based technologies, as well as other specialized product lines used in hospitals and outpatient settings.

Teleflex serves healthcare markets in North America, Europe, Asia and other international regions.